Work

Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.516

Authors: Julia Foldi, Adriana Kahn, Andrea Silber, Tao Qing, Emily Reisenbichler, Neal A. Fischbach, Justin Persico, Kerin B. Adelson, Anamika Katoch, Anees B. Chagpar, Tristen Park, Adam Blanchard, Kim Blenman, David L. Rimm, Lajos Pusztai

Institutions: Yale University, Saint Louis University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: closed

OpenAlex ID: W4281992807

Cites:

Cited by: 1

Related to: 10